Skip to content

Cullinan Therapeutics, Inc. CGEM Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)

Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
$904.56M-3.8%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$116.94M-37.8%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$483.59M+91.1%

Other financials

Income statement

See full
Revenue-
Operating income-$53.7M+2.4%
Net income-$49.7M-2.4%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$75.1M-2.1%
Total debt$2.4M+29.5%
Total equity$408.7M-30.8%
Total assets$403.0M-30.5%

Cash flow

See full
Operating cash flow-$46.0M-6.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.08B+94.2%
Enterprise value$1.01B+114%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio10.3×-1.3×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cullinan Therapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Cullinan Therapeutics, Inc. (CGEM) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $276.8M in Q1 2026.
How has Cullinan Therapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
Cullinan Therapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) increased by 21.8% year-over-year, from $227.17M to $276.8M.
What is the long-term trend for Cullinan Therapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) has grown at a 47.1% compound annual growth rate (CAGR), from $42.01M to $289.56M.
What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.